Immunosuppressant FK506: Focusing on neuroprotective effects following brain and spinal cord injury

The secondary damage that follows central nervous system (CNS) injury is a target for neuroprotective agents aimed at tissue and function sparing. FK506, a clinically used immunosuppressant, acts neuroprotectively in rat models of brain and spinal cord injury and ischemia. Evidence of in vivo experi...

Full description

Saved in:

Bibliographic Details
Published in:	Life sciences (1973) Vol. 91; no. 3-4; pp. 77 - 82
Main Authors:	Saganova, Kamila, Galik, Jan, Blasko, Juraj, Korimova, Andrea, Raekova, Eniko, Vanicky, Ivo
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Inc 21-08-2012
Subjects:	animal models Animals brain Brain - drug effects Combined therapy Disease Models, Animal Dosing regimen Functional outcome Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - pharmacology in vivo studies Inflammation ischemia Ischemia - drug therapy Ischemia - metabolism Neuroprotective Agents - administration & dosage Neuroprotective Agents - pharmacology neuroprotective effect Rats spinal cord Spinal Cord Injuries - drug therapy Tacrolimus - administration & dosage Tacrolimus - pharmacology Tissue sparing Tissue sparing Combined therapy Dosing regimen Functional outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The secondary damage that follows central nervous system (CNS) injury is a target for neuroprotective agents aimed at tissue and function sparing. FK506, a clinically used immunosuppressant, acts neuroprotectively in rat models of brain and spinal cord injury and ischemia. Evidence of in vivo experimental studies highlights the neuroprotective role of FK506 by its direct impact on various cell populations within the CNS. The participation of FK506 in modulation of post-traumatic inflammatory processes is a further potential aspect involved in CNS neuroprotection. In this review we provide an overview of the current laboratory research focusing on the multiple effects of FK506 on neuroprotection following CNS injury. [Display omitted]
Bibliography:	http://dx.doi.org/10.1016/j.lfs.2012.06.022 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Feature-1
ISSN:	0024-3205 1879-0631
DOI:	10.1016/j.lfs.2012.06.022